SKAN Group (SKAN) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
24 Mar, 2026Executive summary
Order intake rose 3.1% to CHF 370.6 million, with strong demand in Europe and a cautious U.S. market; order backlog increased 8.7% to CHF 346.1 million, supporting future visibility.
Net sales declined 7.7% to CHF 333.3 million due to above-average project postponements, mainly vaccine lines, shifting revenue into 2026 and 2027.
EBITDA dropped 32.3% to CHF 38.6 million (margin 11.6%), mainly from lower project business sales and higher operating expenses; profitability rebounded in H2 with a 19% margin.
Two strategic acquisitions (Metronik and ABC Transfer) expanded the high-margin Services and Consumables segment and broadened the offering.
Net profit reached CHF 17.6 million; a dividend of CHF 0.22 per share (30% payout ratio) is proposed.
Financial highlights
Order intake: CHF 370.6 million (+3.1% year-over-year); order backlog: CHF 346.1 million (+8.7%); book-to-bill ratio: 1.1x.
Net sales: CHF 333.3 million (-7.7% year-over-year; -6.4% at constant currency).
EBITDA: CHF 38.6 million (margin 11.6%), with H2 margin at 19%.
Operating cash flow: CHF 64.1 million, supported by advance payments and disciplined working capital.
ROCE: 10.3%, down due to higher capital employed and lower EBIT.
Net debt: CHF 37.4 million; net debt/EBITDA ratio of 0.97x; equity ratio: 26.5%, mainly due to acquisition-related goodwill.
Investments totaled CHF 45.9 million, mainly for Pre-Approved Services development.
Outlook and guidance
2026 sales growth expected in the upper teens percentage range; midterm outlook unchanged with mid to upper teens sales growth and gradual EBITDA margin increase to upper teens.
EBITDA margin forecasted at 13%-15% for 2026.
Management expects a softer H1 2026 due to project timing, with stronger H2 performance anticipated.
Guidance assumes no major tariff escalations, limited impact from geopolitical conflicts, and no significant currency effects.
Services and Consumables, including Pre-Approved Services, are key growth and margin drivers.
Launch of Pre-Approved Services planned for H2 2026, aiming to shorten customers’ time-to-market.
Latest events from SKAN Group
- Order intake up 21.8%, EBITDA margin 15.8%, and dividend up 14% to CHF 0.40 per share.SKAN
H2 20243 Feb 2026 - Net sales up 17.2%, EBITDA margin within guidance, and robust order backlog support outlook.SKAN
H1 202423 Jan 2026 - Record order intake and backlog offset lower sales and EBITDA, supporting a positive outlook.SKAN
H1 202523 Nov 2025 - Digital integration, pre-approved services, and innovation drive growth and market leadership.SKAN
CMD 202515 Nov 2025 - Strong growth in aseptic solutions driven by injectable biotech trends and innovation leadership.SKAN
Investor Presentation19 Jun 2025 - 76% stake acquisition boosts digital transformation and market reach in life sciences.SKAN
M&A Announcement19 Jun 2025